16.03.2020
A breakthrough in the treatment of depression – a medicine that works a few hours after administration.
A new antidepressant in nasal spray with esketamine is one of treatment options for adults with treatment-resistant major depressive episode who have not responded to at least two different antidepressant treatments in the current moderate to severe depressive episode.
- http://www.pharmatimes.com/news/jansse n_submits_spravato_expansion_in_eu_132 2570
- https://www.jnj.com/janssen-seeks-expanded-use-of-spravato-esketamine-nasal-spray-in-europe-as-a-treatment-for-depressive-symptoms-in-adults-with-major-depressive-disorder-who-have-current-suicidal-ideation-with-intent
- https://tech.wp.pl/rewolucja-w-leczeniu-depresji-lek-ktory-daje-efekty-juz-po-kilku-godzinach-6358212554578049a
- https://www.ema.europa.eu/en/documents/ product-information/spravato-epar-product-information_pl.pdf
